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Antiepileptic drug treatment 2011; current limitations and future perspectivesInitiating antiepileptic drug (AED) treatment after a ﬁrst seizure
remains a controversial issue because of our lack of understanding
of the underlying mechanisms of brain injury and the subsequent
processes that lead to injured brain becoming epileptic. Current
treatment for established epilepsy requires long-term treatment
with drugs that have obvious limitations. The currently available
drugs have antiseizure activity but lack antiepileptogenic proper-
ties. Despite extensive mechanistic experimental research being
performed during the last decades, the process of epileptogenesis
remains poorly understood. Consequently, no antiepileptogenic
drugs have been developed yet. Moreover, current AEDs, including
new generation drugs have considerable side effects, both acute
and chronic. Second-generation AEDs may be better tolerated but
are no more effective than traditional AEDs. Because of our lack of
understanding of the underlying mechanism of action of AEDs
attempts to rationally prescribe and combine AEDs in different
types of seizures and epilepsy syndromes have largely failed.1
Clearly, we need to shift gears and change the paradigms for future
drug development in epilepsy.
These fundamental issues were intensively discussed during
the 1st Ghent International Epilepsy Workshop, an international
key opinion leader meeting held in Gent, Belgium on May 21–23,
2010. As a result of this meeting, the current issue of Seizure, the
European Journal of Epilepsy publishes 3 invited reviews by
international experts and groups in the ﬁeld of antiepileptic drug
development and therapy.
Dr. Wolfgang Lo¨scher provides a comprehensive overview of
the current status of animal models for seizures and epilepy. These
models have played a fundamental role in advancing our
understanding of basic mechanisms underlying ictogenesis and
epileptogenesis and have been instrumental in the discovery and
preclinical development of novel AEDs. However, there is growing
concern that the efﬁcacy of drug treatment of epilepsy has not
substantially improved with the introduction of new AEDs. This
may be due to the fact that only the same simple screeningmodels,
i.e., the maximal electroshock seizure (MES) and sc. pentylenete-
trazole (PTZ) seizure tests, have been used in AED discovery. These
old models may identify only drugs that share characteristics with
existing drugs, and are unlikely to have an effect on refractory
epilepsies. Experience with several novel AEDs, including levetir-
acetam, has shown that theMES and PTZmodels do not identify all
potential AEDs andmay fail to discover compounds that have great
potential efﬁcacy but work through mechanisms not tested by
these models. Lo¨scher2 argues that preclinical strategies of AED
discovery and development need a conceptual shift that is moving
away from using models that identify therapies for the symptom-1059-1311/$ – see front matter  2011 British Epilepsy Association. Published by Else
doi:10.1016/j.seizure.2011.03.002atic treatment of epilepsy to those that may be useful for
identifying therapies that are more effective in the refractory
population and that may ultimately lead to an effective cure in
susceptible individuals by interfering with the processes underly-
ing epilepsy.
Furthermore in this issue of Seizure, Dr. Martin Brodie & Dr.
Graeme Sills critically review the limitations of current AEDs in
terms of pharmacological properties and interactions and they
speciﬁcally examine the concept of ‘‘rational polytherapy’’. They
review the available animal and human data exploring the issue
showing that the experimental and clinical evidence in favour of
rational polytherapy is scarse. The only sound evidence available to
support this concept is the positive synergismdemonstrated by the
combination of lamotrigine and valproate. Consequently, robust
information to guide clinicians on when and how to combine
currently available AEDs is necessarily empirical. Despite this lack
of evidence-based data, Brodie and Sills3 argue that the availability
of an increasing number of AEDs with different although
incompletely understood mechanisms of action have provided a
modest improvement in the outcome of epilepsy, in particular in
patients with refractory epilepsy.
Because of the intrinsic limitations of systemic delivery and our
limited understanding of the mechanisms of action of current
AEDs, new and innovative approaches are warranted. Local
delivery of AEDs directly into the brain may be an attractive
treatment option for epilepsy. Higher therapeutic drug levels may
be reached at the targeted brain region and systemic side effects
avoided. In this issue of Seizure, Dr. Annelies Van Dycke et al.4
provide an overview of the currently investigated experimental
and clinical local delivery strategies in the brain ranging from
delivery via pumpmechanisms to more advanced techniques with
cell and gene therapy. They particularly focus on local brain
delivery strategies for epilepsywith special attention to adenosine.
Adenosine is a good candidate for local delivery techniques for
epilepsy because of its proven anticonvulsive effect and it cannot
be given systemically because of systemic side effects. Local
delivery using polymers and pumps are controllable sources, but
have the disadvantage of the need for reﬁlling or replacement.
Transplantation of adenosine releasing stem/neural progenitor
cells can resolve this problem since long-term integration and
secretion of adenosine is possible. Despite the fact that this last
strategy is currently hampered by a limited control on cell
integration and adenosine release after transplantation further
studies with evaluation of long-term effects of cell-based therapies
are warranted. The future of cell-based therapies in epilepsy seems
promising.vier Ltd. All rights reserved.
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